Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Open access
Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, Kroemer, Guido · 2021 · Cell Death & Disease

Abstract

The circulating metabolome provides a snapshot of the physiological state of the organism responding to pathogenic challenges. Here we report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care). This analysis revealed major disease- and stage-associated shifts in the metabolome, meaning that at least 77 metabolites including amino acids, lipids, polyamines and sugars, as well as their derivatives, were altered in critical COVID-19 patient’s plasma as compared to mild COVID-19 patients. Among a uniformly moderate cohort of patients who received tocilizumab, only 10 metabolites were different among individuals with a favorable evolution as compared to those who required transfer into the intensive care unit. The elevation of one single metabolite, anthranilic acid, had a poor prognostic value, correlating with the maintenance of high interleukin-10 and -18 levels. Given that products of the kynurenine pathway including anthranilic acid have immunosuppressive properties, we speculate on the therapeutic utility to inhibit the rate-limiting enzymes of this pathway including indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-021-03540-y

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 168

Metadata

Authors
Danlos, F.-X., Grajeda-Iglesias, C., Durand, S., Sauvat, A., Roumier, M., Cantin, D., Colomba, E., Rohmer, J., Pommeret, F., Baciarello, G., Willekens, C., Vasse, M., Griscelli, F., Fahrner, J.-E., Goubet, A.-G., Dubuisson, A., Derosa, L., Nirmalathasan, N., Bredel, D., Mouraud, S., Pradon, C., Stoclin, A., Rozenberg, F., Duchemin, J., Jourdi, G., Ellouze, S., Levavasseur, F., Albigès, L., Soria, J.-C., Barlesi, F., Solary, E., André, F., Pène, F., Ackerman, F., Mouthon, L., Zitvogel, L., Marabelle, A., Michot, J.-M., Fontenay, M., & Kroemer, G.
Venue
Cell Death & Disease
Published
2021-03-11
Volume
12
Issue
3
Pages
258-258
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3135288125
Cited by
168
References
9
FWCI
10.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. https://app.cochat.ai/papers/10.1038/s41419-021-03540-y
The paper
Danlos, F.-X., Grajeda-Iglesias, C., Durand, S., Sauvat, A., Roumier, M., Cantin, D., Colomba, E., Rohmer, J., Pommeret, F., Baciarello, G., Willekens, C., Vasse, M., Griscelli, F., Fahrner, J.-E., Goubet, A.-G., Dubuisson, A., Derosa, L., Nirmalathasan, N., Bredel, D., . . . Kroemer, G. (2021). Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death & Disease. https://doi.org/10.1038/s41419-021-03540-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.